BIOF: No sales in Q2, but capital raised and promising tests set stage for scale-up and new leadership
· Issued by Biofrigas Sweden AB
Q2 2025 saw no net sales and continued losses, but promising facility tests and a US patent grant position the company for a key scale-up phase. Capital was raised through rights issues and loans, and a CEO transition is set for September.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
